Lack of iron regulating protein contributes to high blood pressure of the lungs

February 14, 2013, National Institutes of Health
Lack of iron regulating protein contributes to high blood pressure of the lungs
Iron regulatory protein 1 (Irp1) detects iron levels in cells and directs either the storage or use of iron, depending on other conditions in the body. The researchers found that mice lacking Irp1 produced high levels of hypoxia inducible factor 2-alpha (HIF2 alpha), a protein produced in response to low oxygen conditions, like those that occur at high altitudes. In turn, HIF2 alpha spurs production of the hormone erythropoietin, which stimulates the production of red blood cells. HIF2 alpha also triggered increased production of a substance known as endothelin-1 in the lungs, which likely contributed to the animals’ development of pulmonary hypertension.

A protein known to regulate iron levels in the body has an unexpectedly important role in preventing a form of high blood pressure that affects the lungs, and in stabilizing the concentration of red cells in blood, according to a study in mice by researchers at the National Institutes of Health. 

In mice, lack of 1 (Irp1) results in pulmonary hypertension, a form of high blood pressure that affects the lungs, and to polycythemia, a rare disorder in which the body produces excess .

"This insight might lead to progress in treating cases of polycythemia or pulmonary hypertension without a known cause," said senior author Tracey A. Rouault, M.D., of the Division of Intramural Research (DIR) at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), where the research was conducted.   It's possible, she added, that human cases of these disorders might result from malfunctioning copies of the gene for Irp1.

The study also provides insight into how the body directs iron into the manufacture of blood to prevent anemia, the deficiency of red .

The findings appear in .

Dr. Rouault collaborated with more than a dozen other NIH researchers, including first authors Manik C. Ghosh, Ph.D., and Deliang Zhang, Ph.D., also of the NICHD's DIR, as well as researchers at the NIH Veterinary Resources Program and the National Heart, Lung and Blood Institute. Researchers from the University of Colorado School of Medicine, Denver, and the University of Nebraska–Lincoln were also part of the team.

Iron regulatory protein 1 (Irp1) detects iron levels in cells and directs either the storage or use of iron, depending on other conditions in the body. The researchers found that mice lacking Irp1 produced high levels of hypoxia inducible factor 2-alpha (HIF2 alpha), a protein produced in response to low oxygen conditions, like those that occur at high altitudes. In turn, HIF2 alpha spurs production of the hormone erythropoietin, which stimulates the production of red blood cells.

When the animals were put on low-iron diets, they did not become anemic, but instead developed polycythemia and pulmonary hypertension.

In people, polycythemia and high in the lungs are rare conditions, and in some cases occur without a known cause. It is possible that changes in the gene for Irp1 may account for some of these cases, the researchers suggest.

To investigate Irp1's role in regulating the body's use of iron, the researchers reared mice lacking the gene that makes Irp1 and divided the animals into two groups, feeding one group a normal diet and the other a low iron diet.

Within a year, less than 40 percent of the mice on the low-iron diet had survived. Most had died from abdominal hemorrhaging. The researchers found that the mice on low iron diets had high levels of HIF2 alpha in the lungs and kidney. These animals produced high levels of erythropoietin, which resulted in polycythemia. HIF2 alpha also triggered increased production of a substance known as endothelin-1 in the lungs, which likely contributed to the development of .

"Irp1 appears to be the switch that controls whether HIF2 alpha protein is made," Dr. Zhang said.

This research also provided insight into how Irp1 functions under normal circumstances Dr. Rouault explained. The researchers theorize that in low-iron conditions, Irp1 allows the production of HIF2 alpha. HIF2 alpha then triggers production of erythropoietin, to generate more red blood cells. To supply iron for the red blood cells, iron is removed from the tissues. When tissue decline too much, Irp1 halts production of HIF2 alpha, and production of new blood cells ceases, conserving the body's remaining iron stores. Production of red blood cells then declines, leading to anemia.

Related Stories

Recommended for you

Researchers devise decoy molecule to block pain where it starts

January 16, 2018
For anyone who has accidentally injured themselves, Dr. Zachary Campbell not only sympathizes, he's developing new ways to blunt pain.

Scientists unleash power of genetic data to identify disease risk

January 16, 2018
Massive banks of genetic information are being harnessed to shed new light on modifiable health risks that underlie common diseases.

Blood-vessel-on-a-chip provides insight into new anti-inflammatory drug candidate

January 15, 2018
One of the most important and fraught processes in the human body is inflammation. Inflammatory responses to injury or disease are crucial for recruiting the immune system to help the body heal, but inflammation can also ...

Molecule produced by fat cells reduces obesity and diabetes in mice

January 15, 2018
UC San Francisco researchers have discovered a new biological pathway in fat cells that could explain why some people with obesity are at high risk for metabolic diseases such as type 2 diabetes. The new findings—demonstrated ...

Obese fat becomes inflamed and scarred, which may make weight loss harder

January 12, 2018
The fat of obese people becomes distressed, scarred and inflamed, which can make weight loss more difficult, research at the University of Exeter has found.

Optimized human peptide found to be an effective antibacterial agent

January 11, 2018
A team of researchers in the Netherlands has developed an effective antibacterial ointment based on an optimized human peptide. In their paper published in the journal Science Translational Medicine, the group describes developing ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.